Systemic amyloidosis is commonly associated with plasma cell dyscrasias, chronic inflammatory conditions, dialysis, or hereditary disorders, with the GI tract being one of several organs affected by amyloid deposition
Current projections suggest that, without effective intervention, nearly two-thirds of adults over 25 years of age could be affected by 2050, corresponding to approximately 3.8 billion individuals [1]
The Emergency Care Access & Timeliness eCQM also incorporates additional metrics to enhance its comprehensiveness and analytic value, including boarding time in the ED, numerator component (3), and time from arrival to placement in a treatment room, numerator component (1), which are not currently captured by any other measure in the Hospital OQR Program
Novo has since launched a broad late-stage program for CagriSema, including the Phase III trials REDEFINE 1, which is assessing its efficacy as a weight loss therapy, and REDEFINE 2, designed to include type 2 diabetes patients with excess body weight
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation